Or so some researchers have asserted in studies over the last half decade, saying that people who attend church regularly, pray or are otherwise involved in religious activities enjoy longer lives and other positive health benefits.
The critics -- who included demonstrators outside the courthouse -- said they believed that approach was unfair for many reasons, and asserted that studies have overstated the number of Jewish survivors in the former Soviet Union.
Finally, despite these limitations, we assert these studies as described are still useful in that they add to the body of knowledge for a set of relatively understudied genes.
Interestingly, in the relatively longer ASSERT study (mean 3-year follow-up) the overall rate of the TE complications was 0.72% per year.
However, like in the SINGLE study, the TDF/FTC-containing arms in the ASSERT and RADAR studies consistently have higher changes from baseline in all BTMs versus the comparator (RAL in ASSERT study, ABC/3TC in RADAR study).
Age was an independent predictor of outcome in the ASSERT study, and significant differences were seen when age was compared between responders and remitters in the GO RAISE study and the combined dataset.
The ASSERT study was primarily designed to evaluate the safety and efficacy of infliximab in patients with AS and was not powered to evaluate correlations between changes in inflammatory markers and clinical measures.
This secondary analysis from the ASSERT study was not powered to assess the significance of relationships between changes in biomarker levels and the BMD of patients with AS who received infliximab.
In Barkham and colleagues' study of very early axSpA (mean symptom duration 15.3 months), infliximab achieved an Assessment of SpondyloArthritis international Society (ASAS) partial remission rate of 56% [ 6], compared with 22% in the registration trial of infliximab in established AS (the ASSERT study).
Similarly, in the INFAST study of infliximab treatment in axSpA patients with disease duration less than 3 years (mean 1.8 to 1.9 years), higher numerical response rates (40% improvement from baseline using the ASAS criteria (ASAS40) of 75%) were observed than in the ASSERT study (ASAS40 of 45%) or trials of the other TNFi agents in established AS (ASAS40 responses of 39 to 47%) [ 7- 10].
